Partnering Deals and Alliances with Big Pharma The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies. To Read The Complete Report Kindly Visit: http://www.marketresearchreports.biz/analysis/164255 For All Latest Reports Kindly visit: http://www.marketresearchreports.biz

1. Partnering Deals and Alliances with Big Pharma
The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth
insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.
Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits: Detailed
partnering activity profiles for each of the top 50 big pharma companies Over 300 charts showing a
company’s dealmaking activity since 2007, allowing quick identification potential partners Partnering
therapy focus revealed Partnering activity since 2007 – number of deals per year Full listing of
partnering deals Activity by deal type Activity by industry sector Activity by phase of development Activity
by technology type Activity by therapeutic area Comprehensive access to over 3,000 partnering deals as
recorded at Current Agreement, together with contract documents if available Insight into the terms included
in a partnering agreement, together with real world clause examples, via contract documents Understand the
key deal terms the company has agreed in previous deals Undertake due diligence to assess suitability of your
proposed deal terms for partner companies The Partnering Deals and Alliances with Big Pharma report
provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds
leading fifty big pharma companies. This premier report provides all the information you require to better
understand big pharma partnering. One of the key aspects of partnering is finding those companies that are
potential candidates for the development and commercialization of the next generation of therapies. A lot of
resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the
company’s business development objectives. Over 300 charts allow quick understanding of each big
pharma companies dealmaking trends over the last four years. This report contains over 3,000 links to online
copies of actual partnering deals as recorded at Current Agreement, together with contract documents if
submitted to the Securities Exchange Commission by bigpharma and their partners. Contract documents
provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of
important issues, many of which will have a significant impact on each party’s ability to derive value
from the deal. The initial chapters of this report provide an orientation of bigpharma’s dealmaking
and business activities. Chapter 1 provides an introduction to the report, whilst
Chapter 2 lists the top 50 leading big pharma companies based on 2012 pharmaceutical revenues and
dealmaking activity since 2007. Chapter 3 reviews the top partnering and M&A deals of 2007-2013
according to reported deal size. Chapter 4 provides a summary on best
practice on how to submit an opportunity to big pharma, to ensure building of relationships and to obtain a
prompt assessment and response from the business development function of the prospective partner. Chapter
5 lists forthcoming partnering events where valuable face to face meetings with big pharma provide a highly
effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated
through numerous back to back meetings. The main body of the report is provided in chapter 6. In-depth
profiles of every big pharma company provide everything required to assess the suitability of a company as a
prospective partner. Each profile includes a company overview, partnering activity according to deal type,
phase of development, therapy area and technology type. Each company profile provides a comprehensive
listing of deal records available at Current Agreements, each of which links direct to an online copy of the
actual deal record plus contract document if filed with the SEC. One of the key aspects of partnering is
conducting due diligence on a partner to determine under what terms a prospective partner agrees to a
partnering relationship. Understanding the flexibility of a prospective partners’ negiotated deals terms
provides critical insight into the negotiation process in termsof what you can expect to achieve during the
negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil
Partnering Deals and Alliances with Big Pharma

2. is in the detail in terms of how payments are triggered – contract documents provide this insight where
press releases and databases do not. This data driven report contains
over 3,000 links to online copies of actual deal records at Current Agreements and contract documents, where
submitted to the Securities Exchange Commission by companies and their partners. Contract documents
provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of
important issues, many of which will have a significant impact on each party’s ability to derive value
from the deal. In addition, contract documents provide the answers to numerous questions about a
prospective partner’s flexibility on a wide range of important issues, many of which will have a
significant impact on each party’s ability to derive value from the deal. In summary, the report
provides the reader with the tools necessary to make successful contact with the right big pharma partners
effectively and efficiently. Key benefits Partnering Deals and Alliances with Big Pharma provides the user
with the following key benefits: Detailed partnering activity profiles for each of the top 50 big pharma
companies Over 300 charts showing a company’s dealmaking activity since 2007, allowing quick
identification potential partners Partnering therapy focus revealed Partnering activity since 2007 –
number of deals per year Full listing of partnering deals Activity by deal type Activity by industry sector
Activity by phase of development Activity by technology type Activity by therapeutic area Comprehensive
access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if
available Insight into the terms included in a partnering agreement, together with real world clause examples,
via contract documents Understand the key deal terms the company has agreed in previous deals Undertake
due diligence to assess suitability of your proposed deal terms for partner companies Report scope
Partnering Deals and Alliances with Big Pharma is intended to provide the reader with an in-depth
understanding of the partnering activities of the leading fifty big pharma companies worldwide, enabling the
effective assessment and selection of partners of choice, based on the latest knowledge of a company’s
partnering. Partnering Deals and Alliances with Big Pharma includes: Detailed company profiles for each
of the top 50 big pharma companies, including: Partnering interests and indications Partnering activity since
2007 Partner companies since 2007 Partnering activity since 2007 by: Partner company Deal type Industry
sector Stage of development Technology type Therapy area Over 300 charts showing the dealmaking activity
of each company since 2007 The tools to enable effective and efficient preparation for partnering negotiation
with big pharma 3,000 partnering deals as recorded at Current Agreement, together with contract documents if
available The leading M&A and partnering deals by value 2007-2013 The Partnering Deals and Alliances
with Big Pharma report also provides comprehensive access to available contract documents for each of the
fifty big pharma companies. Analyzing actual company agreements allows assessment of the following:
What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the
payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key
terms of the agreement defined? How are IPRs handled and owned? Who is responsible for
commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and
publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated?
What happens when there is a change of ownership? What sublicensing and subscontracting provisions have
been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to
differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for
agreement law? Partnering Deals and Alliances with Big Pharma provides the user with the following key
benefits: Detailed partnering activity profiles for each of the top 50 big pharma companies Over 300 charts
showing a company’s dealmaking activity since 2007, allowing quick identification potential partners
Partnering therapy focus revealed Partnering activity since 2007 – number of deals per year Full listing
of partnering deals Activity by deal type Activity by industry sector Activity by phase of development
Activity by technology type Activity by therapeutic area Comprehensive access to over 3,000 partnering deals
as recorded at Current Agreement, together with contract documents if available Insight into the terms
Partnering Deals and Alliances with Big Pharma

3. included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals Undertake due diligence to assess
suitability of your proposed deal terms for partner companies
table Of Content
executive Summary
chapter 1 – Introduction
chapter 2 – Big Pharma Top 50 Dealmaking Activity
2.1. Introduction
2.2. Big Pharma Partnering Over The Years
2.4. Big Pharma Partnering By Deal Type
2.5. Big Pharma Partnering Industry Sector
2.6. Big Pharma Partnering By Stage Of Development
2.7. Big Pharma Partnering By Technology Type
2.8. Big Pharma Partnering By Therapy Area
2.9. Big Pharma M&a Over The Years
chapter 3 – Top Big Pharma Deals By Value
3.1. Introduction
3.2. Big Pharma Partnering
3.3. Big Pharma M&a
chapter 4 – Submitting Opportunities To Big Pharma
4.1. How To Submit An Opportunity
4.2. Opportunity Submission Template
4.3. Sending Emails
4.4. Face To Face At Partnering Events
4.5. Online Submission Forms
chapter 5 – Forthcoming Big Pharma Partnering Events
5.1. Forthcoming Events
chapter 6 – Big Pharma Company Profiles
6.1. Introduction
6.2. Field Definitions
6.3. Company Profiles
abbott
actavis Inc.( Formerly Watson)
allergan
amgen
astellas
astrazeneca
Partnering Deals and Alliances with Big Pharma

4. baxter International
bayer
biogen Idec
boehringer Ingelheim
bristol-myers Squibb
celgene
csl
daiichi Sankyo
dainippon Sumitomo
eisai
eli Lilly
endo Pharmaceuticals
forest Laboratories
fresenius
galderma
gilead Sciences
glaxosmithkline
grifols
hospira
johnson & Johnson
kyowa Hakko Kirin
lundbeck
menarini
merck & Co
merck Kgaa
mitsubishi Tanabe
mylan
novartis
novo Nordisk
otsuka
pfizer
purdue
ranbaxy Laboratories
roche
sanofi
servier
shionogi
shire
stada
takeda
teva
ucb
valeant
warner Chilcott
chapter 7 – Resources
Partnering Deals and Alliances with Big Pharma

5. appendices
appendix 1 – Deal Type Definitions
appendix 2 – Example Contract Document
about Wildwood Ventures
current Partnering
current Agreements
recent Titles From Currentpartnering
order Form – Reports
Market Research Report(http://www.marketresearchreports.biz/) Marketresearchreports.biz is the most
comprehensive collection of market research reports. Marketresearchreports.biz services are especially
designed to save time and money of our clients. We are a one stop solution for all your research needs, our
main offerings are syndicated research reports, custom research, subscription access and consulting services.
We serve all sizes and types of companies spanning across various industries.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.com
Website: www.marketresearchreports.biz
Partnering Deals and Alliances with Big Pharma